Pharmaceutical policy change and the safety of new drugs
Year of publication: |
2002
|
---|---|
Authors: | Olson, Mary K. |
Published in: |
The journal of law & economics. - Chicago, Ill. : Univ. of Chicago Press, ISSN 0022-2186, ZDB-ID 218304-3. - Vol. 45.2002, 2,2, p. 615-642
|
Subject: | Arzneimittel | Pharmaceuticals | Aufsichtsbehörde | Regulatory agency | Dauer | Duration | USA | United States | 1990-1995 |
-
Cost-benefit analysis of the FDA : the case of the prescription drug user fee acts
Philipson, Tomas J., (2008)
-
Regulating advertisements : the case of smoking cessation products
Avery, Rosemary J., (2006)
-
Perverse incentives in the medicare prescription drug benefit
McAdams, David, (2006)
- More ...
-
Olson, Mary K., (2020)
-
Pharmaceutical expenditure and regulatory policy in the NHS
Olson, Mary K., (1992)
-
Regulatory agency discretion among competing industries : inside the FDA
Olson, Mary K., (1993)
- More ...